Christopher Cabell - 18 May 2023 Form 4 Insider Report for Zura Bio Ltd (ZURA)

Reporting relationship: CMO & Head of R&D
Issuer ticker: ZURA
Reported as of: 18 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2023, 21:15:56 UTC
Prior SEC filing: 21 Mar 2023
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Christopher Cabell

Key filing fact

Christopher Cabell filed Form 4 for Zura Bio Ltd (ZURA) on 22 May 2023.

Key facts

This page summarizes Christopher Cabell's Form 4 filing for Zura Bio Ltd (ZURA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 May 2023, 21:15.

Change

Previous filing in this sequence was filed on 21 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZURA transaction

Class A Ordinary Shares

Award

Transaction value: $0
Shares: +162,060
Change %
Price: $0.000000
Shares after: 162,060
Date: 18 May 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted an award of 162,060 Restricted Share Units ("RSUs") on May 18, 2023 (the "Grant Date"). Under the terms of the RSU grant, 25% of the RSUs vest on each of the anniversaries of the Grant Date, such that the RSUs vest equally over four years, subject to the Reporting Person's continued service with the Issuer.